Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia

A subgroup of patients with core binding factor acute myeloid leukemias (AML) is characterized by the presence of the fusion gene CBFb-Myh11. At the cytogenetic level, most of these patients are identified by the presence of an inversion of chromosome 16 [inv(16)(p13q22)] and rarely by a translocation t(16;16)(p13;q22). The aim of this study is to describe the natural history of patients with t(16;16) [N = 6] treated at MD Anderson Cancer Center and compared them with a cohort of patients with inv(16)(p13q22) [n = 61]. In patients with t(16;16) the complete remission rate (CR) was 100% when treated with a combination of fludarabine and high-dose cytarabine. Median overall survival (OS) had not been achieved. There was no difference in response or OS or progression free survival between both groups. Presence of additional chromosomal abnormalities and molecular aberrations had no effect on prognosis. In conclusion, and consistent with previous reports, the natural history of patients with t(16:16)(p13;q22) is similar to that of classic patients with inv16 AML and therefore should be treated similarly.

[1]  R. Grace,et al.  Applicability of 2009 international consensus terminology and criteria for immune thrombocytopenia to a clinical pediatric population , 2012, Pediatric blood & cancer.

[2]  M. Crowther,et al.  The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. , 2011, Blood.

[3]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[4]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[5]  J. George,et al.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. , 2009, Blood.

[6]  A. Salama,et al.  Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies (anti-Rh0(D)) , 1984, Blut.

[7]  C. Martínez-Murillo,et al.  Fc receptor blockade in patients with refractory chronic immune thrombocytopenic purpura with anti-D IgG. , 2002, Archives of medical research.

[8]  G. Buchanan,et al.  Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. , 2002, The Journal of pediatrics.

[9]  R. Domen,et al.  Renal failure after anti-D globulin treatment of idiopathic thrombocytopenic purpura , 2002, Pediatric Nephrology.

[10]  A. Gaines.  Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. , 2000, Blood.

[11]  S. Bertolone,et al.  Treatment of childhood acute immune thrombocytopenic purpura with anti-D immune globulin or pooled immune globulin. , 1999, The Journal of pediatrics.

[12]  C. Bloomfield,et al.  Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. , 1998, Cancer research.

[13]  D. Mauger,et al.  Efficacy, safety, and dose response of intravenous anti-D immune globulin (WinRho SDF) for the treatment of idiopathic thrombocytopenic purpura in children. , 1998, Seminars in hematology.

[14]  R. Ware,et al.  Anti-D: mechanisms of action. , 1998, Seminars in hematology.

[15]  Ping Liu,et al.  Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia. , 1994, Blood.

[16]  F. Collins,et al.  Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. , 1993, Science.

[17]  T. Lister,et al.  Abnormalities of chromosome 16q in myeloid malignancy: 14 new cases and a review of the literature. , 1992, Leukemia.

[18]  Thomas D. Y. Fok,et al.  Chromosome 16 abnormalities associated with myeloid malignancies , 1991, Genes, chromosomes & cancer.

[19]  R. Larson,et al.  Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis. , 1986, Blood.

[20]  R. Larson,et al.  A morphologic and cytochemical study of acute myelomonocytic leukemia with abnormal marrow eosinophils associated with inv(16)(p13q22). , 1984, American journal of clinical pathology.

[21]  R. Larson,et al.  Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association. , 1983, The New England journal of medicine.

[22]  C. Bloomfield,et al.  Partial deletion of the long arm of chromosome 16 and bone marrow eosinophilia in acute nonlymphocytic leukemia: a new association. , 1983, Blood.